BRAF and melanoma: To test the hypothesis that expression of MCL-1, a known anti-apoptotic factor, can contribute to drug resistance, we targeted MCL-1 using a small molecule inhibitor (sabutoclax) in a variety of human melanomas, including BRAFV600E and non-BRAF stage III/stage IV metastatic melanoma cell lines (Table 1).